News – Page 986 – Endpoints News

Shares of Bone Therapeutics dive on PhIII cell therapy failure; GSK-backed Sitryx inks discovery deal

7 years ago

Moment of truth looms for Nektar, Bristol-Myers with a major update to NKTR-214 combo — and the latest snapshot is ...

7 years ago

Bristol-Myers lays off the last 63 staffers at ZymoGenetics, shutters Seattle operations

7 years ago

A star drug in Mallinckrodt’s $1.2B Sucampo buyout flops in pivotal trial

7 years ago

Bound to the hip with Trump, ex-Celgene chief Bob Hugin gets whipped in New Jersey Senate race

7 years ago

The resurrection of LUM001: Mike Grey gets his drug back from Shire — along with $120M to gamble on PhIII trials

7 years ago

Foamix claims goal-winning success in twin pivotal studies for rosacea — shares spike

7 years ago

Dana-Farber team identifies new 'gene traffic control' targets in two rare, aggressive cancers

7 years ago

Centrexion eyes $70M-$80M in IPO with big plans for PhIII non-opioid painkiller

7 years ago

Amgen offers cash and milestones for Provention to take the lead on a celiac drug; Aveo's PhIII fails to impress, ...

7 years ago

Are more immuno-oncology buyouts on the menu at Eli Lilly’s executive suite?

7 years ago

OncoSec’s defense of weak preliminary Tavo data for PD-1 resistant melanoma can’t stop a rout

7 years ago

With its back against the wall, Regulus hands over its lead microRNA drug to Sanofi for a small down payment

7 years ago

Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster ...

7 years ago

Bargain sale continues: AstraZeneca offloads three respiratory drugs to Covis in $350M deal

7 years ago

Floundering in the wake of an FDA approval, Achaogen makes a second round of deep cuts to stay alive

7 years ago

After playing possum in I/O, Eli Lilly shows new signs of life with $40M-plus cash discovery deal for NextCure

7 years ago

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

7 years ago

Regenxbio scores $180M vector deal; Bristol-Myers expands agreement to test Opdivo with Infinity's IPI-549

7 years ago

Need alternative funding channels? Perceptive Advisors now has $675M devoted to those deals

7 years ago

In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus

7 years ago

Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'

7 years ago

Novartis CEO Vas Narasimhan lines up his late-stage blockbuster contenders — mixing old favorites and add-ons

7 years ago

Clearside Bio loses nearly half its value pre-market as lead eye drug fails pivotal test

7 years ago

First page Previous page 983 984 985986987 988 989 Next page Last page